Dermata Therapeutics Financials - Benzinga

Dermata Therapeutics Inc

DRMANASDAQ

Trade with Public

Trade with Public

$1.12

0.021.82%

Last update: Aug 10, 9:04 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Dermata Therapeutics Financials

Dermata Therapeutics (DRMA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 89.33 percent increase over losses of $(4.50) per share

Benzinga Newsdesk

PRO
Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.54) by 1.3 percent. This is a 83.48 percent increase over losses of $(9.20) per share

Benzinga Newsdesk

Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus

U.S. stock futures swung between gains and losses on Tuesday after Monday’s declines. Futures of major benchmark indices were mixed. The Santa Claus rally, which began on Dec. 24 last week, seems to have resumed gains after a day of losses on Monday.

Rishabh Mishra

PRO
Dermata Therapeutics Q3 EPS $(1.65) Misses $(1.59) Estimate

Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.65) per share which missed the analyst consensus estimate of $(1.59) by 3.77 percent. This is a 91.92 percent increase over losses of $(20.41) per share

Benzinga Newsdesk

PRO
Dermata Therapeutics Q2 EPS $(1.66) Beats $(2.90) Estimate

Benzinga Newsdesk

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Avi Kapoor